【从默沙东告别“单一Keytruda神药”时代到中国创新药崛起 新一轮医药投资浪潮席卷全球】智通财经APP获悉,美国医药巨头默沙东(MRK.US)首席执行官罗伯·戴维斯周二接受媒体采访时表示,这家制药巨头的未来增长前景已不再仅仅依赖重磅癌症疗法Keytruda。随着“药王”Keytruda
将于2028年到期,默沙东管理层预计未来五年推出20余款新产品,并以2030年代中期约700亿美元的新增长机会对冲Keytruda专利悬崖。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.